News
Latest news259
Company News
East Bay AI biotech company raises $106 million from Jeff Bezos and others
Profluent Bio, a three-year-old Emeryville company, was the first to show that large language models can generate functional proteins. It went on to design the first CRISPR genome-editing system from scratch, creating an open-source gene editor known as OpenCRISPR-1. With its new-found cash from Altimeter and Bezos Expeditions, it now hopes to continue applying its genome editors into antibodies, enzymes and immune system-triggering antigens. It already has cut deals with a handful of partners, such as life sciences tools company Revvity Inc. (NYSE: RVTY) — the former PerkinsElmer Inc. — agricultural player Corteva Inc. (NYSE: CTVA) and the Rett Syndrome Research Trust, to make custom proteins. Read post
Company News
Profluent Raises $106M to Scale Frontier AI Models for Programmable Biology
Profluent, a leader in frontier AI for protein design, today announced a $106 million financing co-led by Altimeter Capital and Bezos Expeditions, with participation from existing investors including Spark Capital, Insight Partners, and Air Street Capital. This round brings Profluent’s total funding to $150 million and will accelerate its mission to make biology programmable – transforming how therapeutics, diagnostics, agriculture, and biomanufacturing solutions are developed. Read post
Company News
New in vivo gene editing biotech blossoms from CRISPR pioneer Jennifer Doudna’s lab with $82M
A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed with $82 million in funding and a dual-vector approach that the company hopes can enable permanent genome editing with a single dose. The funding total includes a $65 million series A that was led by Third Rock Ventures, with RA Capital Management, Yosemite and Sozo Ventures joining the financing bouquet. Read post
Company News
Jennifer Doudna spinoff aims to turn patients’ immune cells into CAR-T fighters with single shot
A spinout from the lab of Nobel laureate Jennifer Doudna has raised $82 million to create drugs that, with a single infusion, can turn patients’ immune cells into cancer- and autoimmune disease-fighting drones. It’s the latest entrant in a high-stakes race to develop what’s known scientifically as in vivo CAR-T treatments. Today’s CAR-T therapies are highly effective at treating certain blood cancers, but patients’ cells have to be removed, reengineered in a facility, and then reinfused — a toxic, expensive, and cumbersome process. Investors and pharma companies are spending billions to create alternatives that transform patients’ cells in their body. Read post
Company News
Jennifer Doudna startup launches with $82M to apply new CRISPR delivery technology to in vivo CAR-T
Azalea Therapeutics, co-founded by Nobel laureate and CRISPR co-inventor Jennifer Doudna, has raised $82 million to develop therapies based on its so-called Enveloped Delivery Vehicles, or EDVs, it said Tuesday. Its approach aims to merge the perks and overcome the limitations of the two most widely-studied delivery vessels: lipid nanoparticles and viral vectors. Read post
Company News
Why Jennifer Doudna, Reed Jobs and others are backing this East Bay biotech’s in-body cell fix-it shop
Azalea's approach is what scientists call in vivo — or in the living body — reprogramming of immune cells. That is one of the hottest areas of cell therapy research because it could make today's chimeric antigen receptor-T cell, or CAR-T, therapies safer, more efficient and more effective. Additionally, having the body's own cellular machine shop serve as a production line for infection-fighting T cells could shave weeks off the process of manufacturing therapies outside the body. Read post
Press Release
Azalea Therapeutics Launches with $82 Million Financing to Redefine Precision Genomic Medicines by Engineering Cells Directly Inside Each Patient
“At Azalea, we are aiming to make cell therapy as simple as dosing a medicine,” said Jenny Hamilton, Ph.D., co-founder, president and chief executive officer of Azalea Therapeutics. “By combining cell-selective delivery with site-specific genome integration, we can create potent and durable in vivo CAR-T and other cell-based therapies inside the body and extend the reach of genome engineering to many more patients.” Read post
Company News
‘We want to change the world:’ Company says it is creating a new kind of plastic
FutureBio is tackling the problem of plastic pollution head-on by creating what its co-founder describes as a new kind of plastic. Different from both the petroleum-based and the biodegradable ones now in use, it is not only durable but also bio-renewable and easier to recycle, said Zilong Wang. “It proposes a different and a novel plastic, which is different from all other kinds of plastic,” he said. Worldwide, only about 9% of today's plastic is actually recycled. Most of the rest, millions of tons, goes to landfills or ends up in the environment. Even the plastic that is recycled is sent to landfills or incinerators after one or two cycles because the quality of the material degrades. Read post
Bakar Bio Labs News
You Asked, We Answered: Bakar Bio Labs Launches Experts-In-Residence Program
Bakar Bio Labs is proud to introduce our new Experts-in-Residence (XIRs) program, bringing in four inaugural XIRs focused on finance, CMC operations, business development and regulatory affairs to support tenants in biotechnology product development. Although Bakar Bio Labs is an early-stage startup incubator, these experts have a particular focus on later-stage resources to help these companies, especially if they started in academia, succeed beyond their time here. Eda Altiok, who just joined us as director of partnerships, says that meetings with the XIRs are available at both set times, and on-demand. “What I kept hearing [from tenants] was that they needed access to industry, access to personnel, and people who’ve encountered similar challenges to what they’re going through, and how to overcome those challenges,” Eda says. “We want them to feel like we’re setting them up for success at Bakar Labs, so we’re excited to unveil this program.” Read post
Company News
Marco Lobba Wins 2025 Biocom Catalyst Award: Precision Therapeutics at the Molecular Level
Marco Lobba co-founded CatenaBio to advance targeted therapeutics at the intersection of chemistry and molecular biology. He co-invented the CysTyr platform, enabling precise conjugation of multiple payloads to antibodies for oncology, gene therapy and cell-based therapies. “I truly believe that the biggest challenge in making new therapeutics is how to direct them in the body,” he says. Dr. Lobba earned his Ph.D. at UC Berkeley, training with Nobel Laureate Jennifer Doudna, and holds numerous patents. Beyond CatenaBio, he mentors scientists, supports food equity programs and advocates for investment in basic research to drive future breakthroughs. Read post
Workforce Development
From Bakar to Breakthrough: How a QWEST Internship Sparked an NSF Fellowship
In early 2024, Greg Timblin sought an intern who could bring dedication, curiosity, and a fresh perspective to his startup, Inapill. UC Berkeley undergrad Katie Sie was eager to expand her skills beyond the classroom and into the fast-moving world of therapeutic innovation. QB3’s QWEST program, which pairs students with Bakar Labs tenant companies for hands-on research, offered the perfect match – one that would lead Katie to a prestigious PhD fellowship. Read post
Company NewsBakar Bio Labs News
AI Development at UC Berkeley’s Top Biotech Incubator, Bakar Bio Labs
AI has taken the world by storm. On the scientific front, the ability to mine huge datasets and make informed, actionable predictions has accelerated the pace of innovation. So it makes sense that startups at UC Berkeley’s Bakar Bio Labs, the university’s leading biotech incubator, would embed AI into their work to discover new medicines, redesign how they are delivered, and even create entirely new biological tools. Bakar Bio Labs’ tenant companies are redefining the world of biotech, and they’re doing it with out-of-the-box solutions. For three of the tenants — Insamo, Aikium, and Profluent — AI is core to their technology and strategy. Read post
Company News
ResVita Bio Announces Positive FDA Pre-IND Meeting, Advancing RVB-003 Toward IND Filing for Netherton Syndrome in Early 2026
ResVita Bio, a biotechnology company pioneering continuous protein therapy for skin diseases, today announced the successful completion of a face-to-face Pre-Investigational New Drug (Pre-IND) meeting with the U.S. Food and Drug Administration (FDA) for RVB-003, its lead investigational therapy for Netherton Syndrome, a chronic and life-threatening genetic skin disorder. Read post
Bakar Bio Labs News
Event Recap: Bakar Bio Labs Showcase 2025
“We recently passed several milestones,” said our director David Schaffer. “We welcomed our 50th tenant company; our tenants have raised more than $750 million since we opened in November 2021, and they've created more than 450 jobs in the Bay Area. This showcase brings investors together with our startup companies to fuel their growth, which is so important not just to us, but to our regional and state economy.” The showcase included a lightning pitch session. “We're really excited about pushing the boundaries of in vivo cellular engineering,” said Jenny Hamilton, CEO and co-founder of Azalea Therapeutics. “We have an initial focus on in vivo car T generation, and what we have invented at Azalea is the ability to do both cell type specific delivery and site specific genomic modification. And so this makes in vivo cell car T therapies safer and more effective. I'd be happy to talk to anybody here. We're at Table 13.” Read post
Tenant Spotlight
From 0 to 100: How Editpep’s CRISPR Technology and Business Took Off at Bakar Bio Labs
"Editpep is a great example of what can happen when UC Berkeley’s innovation and entrepreneurship ecosystem comes together,” says Darren Cooke, Interim Chief Innovation & Entrepreneurship Officer at UC Berkeley. “Through LSEC’s Venture Grant Program, we were able to connect Editpep with funding, mentorship, and key resources like Berkeley SkyDeck, I-Corps and Bakar Bio Labs, paving a path from lab discovery to long-term societal benefit. Helping Ross Wilson and Dana Foss build a business around extraordinary technology has been very rewarding.” Read post
Bakar Bio Labs News
Former QWEST Intern Nam Pianapitham Takes Job at VC Fund
By working at Bakar Bio Labs, she saw firsthand that innovation happens at every level. “Everyone’s working hard towards a goal—even if that goal is five or 10 years down the line, in terms of FDA approval or commercializing technology,” says Nam. Her time as an intern also gave her the confidence to realize that students can make meaningful contributions to the biotech community. Now at Disrupt Health, Nam applies that same passion on a global scale, leveraging the knowledge she acquired during her time as an intern. The fund invests in transformative areas, including self-care, preventive health, age-well technologies, AI-enabled smart hospitals, and digital health platforms. Read post
Press Release
Nosis Bio Announces Development Candidate Nomination for Lead Fibrosis Program
Nosis Bio, an AI-native biotechnology company pioneering cell-targeted gene silencing, today announced the nomination of its first development candidate (DC) for fibrosis. The milestone marks the company’s transition into IND-enabling studies and the advancement of its proprietary targeted delivery and drug design platform into clinical-stage development. Fibrosis affects over 100 million people globally and remains a high-burden, underserved condition that causes progressive scarring of critical organs such as the lungs, kidneys, and heart. Despite its prevalence, the field has seen limited progress, with existing treatments offering only modest efficacy and being constrained by systemic toxicity and poor tolerability. Read post
Company News